AMSTERDAM, BOSTON, and SEATTLE – Sept. 18, 2025 (cGxP.wire) – VectorY Therapeutics, a biotechnology company pioneering vectorized antibody therapies for neurodegenerative diseases, and Shape Therapeutics (ShapeTX), a leader in AI-driven RNA and genetic medicine platforms, today announced a major option and license agreement. The deal centers on Shape’s engineered AAV5-derived deep-brain penetrating capsid (SHP-DB1), granting VectorY exclusive rights to evaluate and potentially license the technology for vectorized antibody delivery against three therapeutic targets.
If successfully executed, this collaboration could accelerate the development of transformative therapies for ALS, Huntington’s disease, and Alzheimer’s disease, areas of high unmet medical need.
Science Significance
The partnership leverages Shape’s SHP-DB1 AAV5-derived capsid, which has demonstrated superior penetration into deep brain regions while reducing off-target toxicities in the liver and dorsal root ganglion. This innovation allows for intravenous (IV) delivery of vectorized antibodies, enabling therapies to reach previously inaccessible neuronal populations. For VectorY, whose pipeline already centers on AAV5-based therapies such as VTx-002 (ALS) and VTx-005 (Alzheimer’s disease), the deal strengthens their scientific foundation and enhances their ability to tackle multiple CNS disorders.
Regulatory Significance
The U.S. FDA and EMA have prioritized therapies addressing neurodegenerative diseases due to their high burden and lack of curative options. VectorY’s IND and CTA submission for VTx-002 is expected by the end of 2025, and adding SHP-DB1 into its pipeline positions the company to accelerate future filings. Regulatory agencies are increasingly supporting first-in-class gene therapies that address unmet medical needs, potentially giving this collaboration access to breakthrough and accelerated approval pathways.
Advertisement
Business Significance
Under the agreement, ShapeTX will receive an upfront payment and stands to gain up to $1.2 billion in milestone payments, with $338 million tied to rare disease programs and $503.5 million tied to non-rare disease programs, plus tiered royalties on sales of licensed products. This demonstrates not only the high commercial potential of AAV5-based therapies but also the confidence in VectorY’s ability to advance these programs into clinical and commercial stages.
Patients’ Significance
For patients, the collaboration represents new hope in devastating conditions. ALS, Huntington’s, and Alzheimer’s remain among the most difficult neurological diseases to treat, with few effective disease-modifying therapies. By combining VectorY’s vectorized antibody technology with ShapeTX’s SHP-DB1 delivery platform, patients may one day benefit from non-invasive, one-time treatments that preserve brain health and slow disease progression.
Policy Significance
Global health policy increasingly emphasizes innovation in neurodegeneration as populations age and CNS diseases become more prevalent. This collaboration aligns with international policy priorities, including the EU’s Neurodegenerative Disease Research Initiative and U.S. NIH’s BRAIN Initiative, by fostering public-private partnerships that advance cutting-edge science. It also reinforces the case for policy support in reimbursement and access frameworks for gene and vectorized antibody therapies.
Transaction Highlights
Under the agreement, VectorY Therapeutics gains an exclusive option to evaluate Shape Therapeutics’ SHP-DB1 AAV5-derived CNS capsid for vectorized antibody delivery against three therapeutic targets. If the evaluation proves successful, VectorY may exercise its option to secure an exclusive license for SHP-DB1 in these indications. Shape will provide access to its proprietary capsid technology, while VectorY will assume responsibility for advancing development and commercialization of the resulting therapies. The deal includes an upfront payment to Shape and the potential for up to $1.2 billion in milestone fees, structured across both rare and non-rare disease programs. Specifically, Shape is eligible for up to $338 million in regulatory, development, and commercial milestones tied to rare disease programs, and up to $503.5 million for non-rare disease programs, along with tiered royalties on future net sales of licensed products. This structure underscores the significant commercial and scientific potential of the collaboration, while aligning incentives for both partners to bring innovative neurodegenerative disease therapies to market.
Source: VectorY Therapeutics Press Release
